Artiva Biotherapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $-47.4M | $-50.7M | $3.3M | $7.1M |
| FY2024 | $-55.0M | $-55.7M | $642.0K | $7.0M |
| FY2025 | $-76.8M | $-79.3M | $2.6M | $6.8M |
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $-47.4M | $-50.7M | $3.3M | $7.1M |
| FY2024 | $-55.0M | $-55.7M | $642.0K | $7.0M |
| FY2025 | $-76.8M | $-79.3M | $2.6M | $6.8M |